AstraZeneca has re-upped its UNICEF-partnered Young Health Programme (YHP), committing to a new five-year phase that will ...

Despite hitting a speed bump over the summer, automated cell therapy manufacturing specialist Cellares has continued to sign new partners at a steady pace, now inking a second agreement with an ...

Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said. | Sign-ups for Medicare’s GLP-1 coverage plan ...

Novo  may be willing to transition some of its shares to the New York Stock Exchange in an effort to woo U.S. investors.  | The Ozempic and Wegovy maker's CEO said he's open to a direct listing of ...

Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...

Par Health has issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection ...

AI is a theme on the mind of every pharma marketer these days as the evolving technology continues to hold an increasingly important role in the field. | Genentech's chief marketing officer Zoë ...

As China and the U.S. presently duke it out over biopharma innovation supremacy, a clutch of Europe’s biggest drugmakers are calling on the bloc to not lose sight of its R&D roots. | As China and the ...

Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...

Bayer has decided to offload its aging cancer drug Stivarga to German compatriot Grünenthal as competition mounts. | Bayer has decided to offload its aging cancer drug Stivarga to German compatriot ...

AI is already changing how pharma marketers work, from summarizing research to analyzing campaign performance and identify ...